You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
M2Gen has seen its research database grow substantially, but now the firm must make the data useful across its clinical, pharma, and MDx partners.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.
Ten sites across the US will seek to integrate genomic risk assessment into clinical care, with a focus on diverse populations.
The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
Nvidia customers in the US and the Middle East expect that the newly introduced A100 servers will accelerate research into the novel coronavirus.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts.
The company said it will use the funds in part to continue development of its artificial intelligence-based proteome-wide drug discovery platform.
Facing questions over data security in the US and Ireland, the company has changed its name as it looks to shed its China operations.
Working with clinical decision support vendor ActX, the suburban Chicago health system has seen strong demand for PGx and genetically informed preventive care.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
The deal expands Illumina's cloud-based data analysis portfolio and gives its customers access to tools to boost assay and operational efficiency.
OnRamp Bio's Rosalind genomic informatics platform will replace Canopy's legacy bioinformatics platform as the CRO expands into the clinical market.
The collaboration will allow oncologists a streamlined view of the treatments and trials available to patients based on their genomic profile.
Researchers from startup Duality Technologies and Dana-Farber have demonstrated the efficacy and speed of a highly secure technique for analyzing encrypted genomic data.
A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.
Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.
The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.
In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.